News & Events

News September 8, 2026

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside...

News August 27, 2026

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation

BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation Peer-reviewed...

News July 29, 2026

BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026

BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ &...

Events November 9 - November 11, 2026

Cologne, Germany

BIO-EUROPE 2026

BrainsWay will be participating in BIO-Europe 2026, taking place on November 9–11, 2026, in Cologne,...

Events October 15 - October 17, 2026

Naples, Italy

7TH EUROPEAN CONFERENCE ON BRAIN STIMULATION IN MENTAL HEALTH

BrainsWay will be participating in the 7th European Conference on Brain Stimulation in Mental Health,...

Events, News September 30 - September 30, 2026

Rotterdam, The Netherlands

ISAM Global Addiction Therapeutics Innovation Day (GATID) 2026

BrainsWay will be participating in the ISAM Global Addiction Therapeutics Innovation Day (GATID), taking...

In the media July 9, 2026

Lifestyle 5 of America’s greatest medical breakthroughs revealed as the nation marks 250 years

For most of America’s 250 years, mental illness was largely treated indirectly with medication, or...

In the media July 1, 2026

BrainsWay Featured in USA Today: America250

BrainsWay was featured in USA Today for its leadership in advancing Deep TMS™, a noninvasive treatment...

In the media November 24, 2025

FDA grants 510(k) clearance for TMS as adjunctive for major depressive disorder in young people

Key takeaways: BrainsWay Deep TMS is cleared for use by adolescents and adults with major depressive...